Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Avlonsulfon
Synonyms :
dapsone
Class :
Antileprosy agents
Brand Name :
Avlonsulfon
Synonyms :
dapsone
Class :
Antileprosy agents
Dosage Forms & Strengths
Tablet
25mg
100mg
50 mg orally each day
Titrate the dose to 300 mg each day or higher to get the desired effect
Later, reduce the dose to the minimum least effective in the range of 50-300 mg/day
100 mg orally each day, combined with other antileprosy agents
Dosage Forms & Strengths
Tablet
25mg
100mg
1-2 mg/kg orally each day
Do not exceed 100 mg/day when combined with antileprosy agents
Administer the dose for a minimum of 3 years by combining it with a multidrug regimen like rifampin
Refer to the adult dosing
may enhance the risk of adverse effect of dapsone
may enhance the risk of adverse effect of dapsone
may enhance the risk of adverse effect of dapsone
may enhance the risk of adverse effect of dapsone
may enhance the risk of adverse effect of dapsone
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may enhance the area under the curve when co-administered
may increase the toxic effect of Methemoglobinemia Associated Agen
may enhance the toxic effect of each other when combined
may enhance the area under the curve when co-administered
bupivacaine: it may increase the risk of methemoglobinemia agents
benzyl alcohol: it may increase the risk of methemoglobinemia agents
capecitabine: it may increase the risk of methemoglobinemia agents
capsaicin: it may increase the risk of methemoglobinemia agents
diphenhydramine: it may increase the risk of methemoglobinemia agents
dyclonine: it may increase the risk of methemoglobinemia agents
estetrol: it may increase the risk of methemoglobinemia agents
furosemide: it may increase the risk of methemoglobinemia agents
levobupivacaine: it may increase the risk of methemoglobinemia agents
lidocaine: it may increase the risk of methemoglobinemia agents
mepivacaine: it may increase the risk of methemoglobinemia agents
nedaplatin: it may increase the risk of methemoglobinemia agents
acemetacin: it may increase the risk of methemoglobinemia agents
acetazolamide: it may increase the risk of methemoglobinemia agents
acetylsalicyclic acid: it may increase the risk of methemoglobinemia agents
amiloride: it may increase the risk of methemoglobinemia agents
amitriptyline: it may increase the risk of methemoglobinemia agents
ammonium chloride: it may increase the risk of methemoglobinemia agents
benorilate: it may increase the risk of methemoglobinemia agents
benserazide: it may increase the risk of methemoglobinemia agents
benzatropine: it may increase the risk of methemoglobinemia agents
bepotastine: it may increase the risk of methemoglobinemia agents
bismuth subgallate: it may increase the risk of methemoglobinemia agents
bisoxatin: it may increase the risk of methemoglobinemia agents
pheneticillin: it may increase the risk of methemoglobinemia associated agents
cinchocaine: it may increase the risk of methemoglobinemia associated agents
doxycycline: it may increase the risk of methemoglobinemia associated agents
enoxacin: it may increase the risk of methemoglobinemia associated agents
eravacycline: it may increase the risk of methemoglobinemia associated agents
moricizine: it may increase the risk of methemoglobinemia associated agents
oxybuprocaine: it may increase the risk of methemoglobinemia associated agents
piperazine: it may increase the risk of methemoglobinemia associated agents
promazine: it may increase the risk of methemoglobinemia associated agents
spirapril: it may increase the risk of methemoglobinemia associated agents
carvedilol: it may increase the risk of methemoglobinemia associated agents
ambroxol: it may increase the risk of methemoglobinemia agents
amikacin: it may increase the risk of methemoglobinemia agents
aminophenazone: it may increase the risk of methemoglobinemia agents
alteplase: it may increase the risk of methemoglobinemia agents
ceforanide: it may increase the risk of methemoglobinemia agents
bicisate: it may increase the risk of methemoglobinemia agents
bleomycin: it may increase the risk of methemoglobinemia agents
bivalirudin: it may increase the risk of methemoglobinemia agents
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
May increase the QTc-prolonging effect of each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
may increase the hypoglycemic effect of Agents with each other when combined
alogliptin: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
balsalazide: it may increase the risk of methemoglobinemia agents
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
methemoglobinemia associated agents may enhance the adverse/toxic effect of local anesthetics
may enhance the risk of adverse/toxic effect of dapsone
may enhance the risk of adverse/toxic effect of dapsone
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
methemoglobinemia associated agents: they may increase the toxic effect when combined with local anesthetics
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
Combining dapsone with pranlukast may cause a reduction in the dapsone’s metabolism
Combining tegafur with dapsone can reduce tegafur’s metabolism
When alprazolam and dapsone is used together, this leads to reduction in the alprazolam’s metabolism
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
It may enhance the risk of adverse effects when combined with protein kinase inhibitors
When acetohexamide is used together with dapsone, this lead to reduction in acetohexamide’s metabolism
When dapsone is used together with acepromazine, this leads to enhanced risk or seriousness of QTc prolongation
dapsone: they may increase the hypertensive effect of sympathomimetics
dapsone: they may increase the hypertensive effect of sympathomimetics
dapsone: they may increase the hypertensive effect of sympathomimetics
dapsone: they may increase the hypertensive effect of sympathomimetics
dapsone: they may increase the hypertensive effect of sympathomimetics
dapsone: it may increase the risk of methemoglobinemia with ambroxol
when both drugs are combined, there may be a decreased metabolism of etoposide
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be an increased risk of nerve damage
the effect of dapsone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
trimethoprim increases the concentration of dapsone in serum
pramoxine /hydrocortisone topical
may increase the adverse effect
may increase the toxic effect
may increase the toxic effect
may increase the toxic effects of local anaesthetics
adapalene and benzoyl peroxide
may increase the toxic effect of benzoyl peroxide
may increase the toxic effect of local anesthetics
may increase the toxic effect of local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may have an increasingly adverse effect when combined with local anesthetics
may increases the adverse effect of Local Anesthetics
may increase the adverse effect of Local Anesthetics
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with methemoglobinemia agents
may have an increasingly adverse effect when combined with prilocaine
may increase the toxic effect of Methemoglobinemia Associated Agents
sodium thiosulfate & sodium nitrite
may have an increasingly adverse effect when combined with sodium nitrite
may increase the toxic effect of Methemoglobinemia Associated Agents
may increase the toxic effect of Local Anesthetics
may increase the adverse effect of Methemoglobinemia Associated Agents
may increase the adverse effects when combined
may have an increasingly adverse effect when combined with methemoglobinemia agents
may increase the adverse effect of local anesthetics
trimethoprim: they may enhance the serum concentration of dapsone
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
may enhance the toxic effect of each other when combined
dichlorphenamide : it may increase the toxic effect of Methemoglobinemia Associated Agents
cimetidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
bupropion : it may increase the toxic effect of Methemoglobinemia Associated Agents
amphetamine : it may increase the toxic effect of Methemoglobinemia Associated Agents
guanethidine : it may increase the toxic effect of Methemoglobinemia Associated Agents
labetalol : it may increase the toxic effect of Methemoglobinemia Associated Agents
tramadol : it may increase the toxic effect of Methemoglobinemia Associated Agents
azithromycin: it may increase the risk of methemoglobinemia agents
betaine: it may increase the risk of methemoglobinemia agents
bevacizumab: it may increase the risk of methemoglobinemia agents
abiraterone: it may increase the risk of methemoglobinemia agents
acetohexamide: it may increase the risk of methemoglobinemia agents
bedaquiline: it may increase the risk of methemoglobinemia agents
benazepril: it may increase the risk of methemoglobinemia agents
calfactant: it may increase the risk of methemoglobinemia agents
cannabidiol: it may increase the risk of methemoglobinemia agents
penfluridol: it may increase the risk of methemoglobinemia agents
pentoxyverine: it may increase the risk of methemoglobinemia agents
acenocoumarol: it may increase the risk of methemoglobinemia agents
by altering metabolism, the levels of dapsone may be reduced
bacitracin: it may decrease the excretion rate of metheglobinemia associated agents
baclofen: it may decrease the excretion rate of metheglobinemia associated agents
baricitinib: it may decrease the excretion rate of metheglobinemia associated agents
capreomycin: it may decrease the excretion rate of metheglobinemia associated agents
carbamazepine: it may decrease the excretion rate of metheglobinemia associated agents
carbidopa: it may decrease the excretion rate of metheglobinemia associated agents
diclofenac: it may decrease the excretion rate of metheglobinemia associated agents
diclofenamide: it may decrease the excretion rate of metheglobinemia associated agents
dicyclomine: it may decrease the excretion rate of metheglobinemia associated agents
diflunisal: it may decrease the excretion rate of metheglobinemia associated agents
diflucortolone: it may decrease the excretion rate of metheglobinemia associated agents
chloroprocaine: it may increase the risk of methemoglobinemia associated agents
cinoxacin: it may increase the risk of methemoglobinemia associated agents
ciprofloxacin: it may increase the risk of methemoglobinemia associated agents
doxacurim: it may increase the risk of methemoglobinemia associated agents
estradiol: it may increase the risk of methemoglobinemia associated agents
pyronaridine: it may increase the risk of methemoglobinemia associated agents
perphenazine: it may increase the risk of methemoglobinemia associated agents
celiprolol: it may increase the risk of methemoglobinemia associated agents
chlorothiazide: it may increase the risk of methemoglobinemia associated agents
chlorpromazine: it may increase the risk of methemoglobinemia associated agents
ergometrine: it may increase the risk of methemoglobinemia associated agents
Actions and Spectrum:
Dapsone inhibits folic acid synthesis in bacteria aiding their growth and survival. It also has anti-inflammatory properties which treats dermatitis herpetiformis and acne. Its spectrum includes other bacteria and protozoa which commonly causes pneumonia in immunocompromised individuals.
Frequency Defined
1-10%
Methemoglobinemia
Hemolysis
<1%
Insomnia
Headache
Nausea
Vomiting
Exfoliative dermatitis
Anemia
Photosensitivity
Hepatitis
Cholestatic jaundice
Leukopenia
Agranulocytosis
Tinnitus
SLE Peripheral neuropathy
Blurred vision
Black Box Warning:
None
Contraindication/Caution:
Dapsone is safe but it may be contraindicated or require caution in certain situations. Hypersensitivity, G6PD deficiency, pregnancy/breastfeeding, liver/kidney disease, drug interactions, and methemoglobinemia are some of the potential contraindications.
Pregnancy consideration:
Category C
Breastfeeding warnings:
dapsone is not compatible during nursing/breastfeeding
Pregnancy category:
Pharmacology:
Pharmacodynamics:
Dapsone is a sulfone medication used to treat various medical conditions by inhibiting folic acid synthesis in bacteria and protozoa which suppress the immune response and reduce inflammatory mediator production.
Pharmacokinetics:
Absorption
Well absorbed
The peak plasma concentration is 4-8 hours.
Distribution
The protein-bound is 70-90%.
Volume of distribution shows 1.5 L/kg
Metabolism
Metabolized by P450 enzymes CYP2E1 and CYP3A4
Elimination and Excretion
The half-life is 28 hours
Administration:
It is given orally in the tablet form and dosage depends on patient age, weight, and health.
Patient information leaflet
Generic Name: dapsone
Pronounced: dap-sone
Why do we use dapsone?
Dapsone treats leprosy and dermatitis herpetiformis. It inhibits bacterial growth and controls the symptoms which is often combined with other treatments. It reduces inflammation and suppresses the immune system response to the persistent itchy rash.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
